This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver?
by Moumi Mondal
HOLX eyes a Breast Health rebound in Q4, backed by leadership changes, new strategy and Endomag momentum.
Hologic Rides on AI-Powered Breast Health Innovations: What's Next?
by Moumi Mondal
HOLX advances breast health with AI tools like Genius Detection PRO and the upcoming Envision 3D platform.
Can Revenue Cycle Operations Drive DVA Stock Before Q1 Earnings?
by Zacks Equity Research
Continued strength in revenue cycle operations is likely to have boosted DaVita's top line in the first quarter despite supply challenges weighing on its performance.
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health (ELAN) delivered earnings and revenue surprises of 19.35% and 2.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 15.13% and 1.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 2.79% and 1.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 46.67% and 4.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Q4 Earnings Lag Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -12.16% and 4.33%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate RadNet (RDNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in RadNet (RDNT): Can Its 5.9% Jump Turn into More Strength?
by Zacks Equity Research
RadNet (RDNT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Mixed Bag for UnitedHealth: Q4 Earnings Beat, Revenues Fall Short
by Zacks Equity Research
UNH projects revenues between $450 billion and $455 billion for 2025.
Do Options Traders Know Something About RadNet (RDNT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to RadNet (RDNT) stock based on the movements in the options market lately.
RDNT Stock Up Post New Tie-Up to Boost Ultrasound Workflows With AI
by Zacks Equity Research
RadNet's latest collaboration aims to create an AI-powered SmartTechnology to improve patient experience and operational efficiency in ultrasound.
RDNT Stock Up Following the New Tie-Up to Leverage Radiology AI
by Zacks Equity Research
RadNet's latest collaboration aims to create an AI control system for image interpretation to ensure AI scalability, performance monitoring and safety.
SYK Stock Rises Following the Launch of Next Generation SurgiCount+
by Zacks Equity Research
Stryker launches the next generation of SurgiCount+ to boost sponge management and blood loss assessment in hospitals.
GEHC Stock Falls Despite FDA Clearance for SIGNA MAGNUS MRI System
by Zacks Equity Research
GE Healthcare receives FDA clearance for its head-only SIGNA MAGNUS 3.0T MRI System.
Cardinal Health Stock Gains Following Two Strategic Acquisitions
by Zacks Equity Research
CAH announces two strategic acquisitions to strengthen its multi-specialty and at-Home Solutions businesses.
Integer Holdings Gains 40.8% YTD: What's Driving the Stock?
by Zacks Equity Research
ITGR shares gain on the back of growth in the Medical segment. However, fluctuations in the oil and energy market are concerning.
Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y
by Zacks Equity Research
NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.
BRKR Stock Declines Despite Launching EpicIF Technology for CellScape
by Zacks Equity Research
Bruker's new technology, EpicIF, is set to enhance the CellScape Precise Spatial Proteomics platform.
QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
by Zacks Equity Research
PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.
XRAY Q3 Earnings & Revenues Beat Estimates, 2024 Guidance Revised
by Zacks Equity Research
DENTSPLY SIRONA's third-quarter results showcase strong top-line growth in the Essential Dental Solutions segment. However, the lowered outlook for fiscal 2024 is a cause of concern.
LifeStance Health Group (LFST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 71.43% and 3.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Cencora Q4 Earnings & Revenues Beat Estimates, Margins Decline Y/Y
by Zacks Equity Research
COR's fourth-quarter fiscal 2024 results showcase a strong segmental performance.